The National Association of Patent Practitioners and the American Council of the Blind, along with other unnamed groups, are bolstering Vanda Pharmaceuticals in its U.S. Supreme Court appeal regarding patent decisions that seemingly invalidated the patent rights for its medication, Hetlioz. Hetlioz is a prominent drug developed for visually impaired individuals.
The appeal’s machinations and eventual outcome could set a precedent with potential ripple effects throughout the major pharmaceutical and legal sectors. The supporting groups are likely to see this as an important stand for exacting and upholding patent rights in the notoriously complex world of pharma.
For more details about the developments in this high-court patent case, you can refer to the original Law360 article.